Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lilly Puts On A Happy Face, But Will Investors Buy In?

Executive Summary

It was all about the pipeline during Eli Lilly's fourth quarter earnings call, as company execs strove to convince analysts they can compensate for revenue losses from big-ticket products about to lose patent protection

You may also be interested in...



FDA Recommends Genetic Testing For Plavix, Opens Window For Effient

FDA's latest revision to Plavix labeling on the issue of poor response in slow metabolizers has heightened the concerns to the highest level - that of a "black box" warning - and recommends use of testing to identify genetic differences in patients' metabolizing function. But FDA officials note that the testing won't be practical in all treatment settings - which leaves another opening for Lilly/Daiichi Sankyo to push use of their competitor Effient

FDA Recommends Genetic Testing For Plavix, Opens Window For Effient

FDA's latest revision to Plavix labeling on the issue of poor response in slow metabolizers has heightened the concerns to the highest level - that of a "black box" warning - and recommends use of testing to identify genetic differences in patients' metabolizing function. But FDA officials note that the testing won't be practical in all treatment settings - which leaves another opening for Lilly/Daiichi Sankyo to push use of their competitor Effient

FDA Recommends Genetic Testing For Plavix Response, Opens Window For Effient

FDA increased the level of its Plavix warning for slow metabolizers to a black box, recommending genetic testing and advising health care professionals to consider using other anti-platelet medications or alternative dosing strategies.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS051890

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel